<DOC>
	<DOCNO>NCT01449006</DOCNO>
	<brief_summary>HIV relate cognitive impairment still occur despite highly active antiretroviral therapy ( HAART ) . HIV disease affect brain 20-40 % patient advance HIV disease; lead vary degree cognitive impairment , recently term HIV associate neurocognitive disorder ( HAND ) . HAND may occur patient virally suppress blood CSF . Patients HIV Associated Neurocognitive Disorders ( HAND ) virally suppress blood cerebrospinal fluid ( CSF ) , whilst highly active antiretroviral therapy ( HAART ) regimen may significant cognitive improvement HAART intensification medication Maraviroc; compare remain exist regimen . This study prospective , interventional , randomise unblinded control clinical trial . The aim study determine whether HAART intensification medication Maraviroc , lead significant improvement HIV associate neurocognitive disorder ( HAND ) . Patients recent progression ( within 6 month ) HAND ( validated neuropsychological assessment ) HAART , virally suppress ( &lt; 50 copy per ml ) blood CSF randomise exist HAART regimen intensify Maraviroc , . The control arm remain medication regimen prescribe . The target enrol 70 patient control group , 70 patient Maraviroc intensification group . Patients undergo baseline neuropsychological testing , MRI , blood test , cerebrospinal fluid ( CSF ) test ( via lumbar puncture ) . The method use determine effectiveness add Maraviroc , include neuropsychological assessment 6 month , neuropsychological assessment , MRI CSF assessment 12 month . Neuropsychological testing complete 6 12 month complete `` blind assessor '' , knowledge arm ( treatment control ) participant enrol . An evaluation ( neuropsychological testing ) perform patient deteriorate course study , recognise patient 's managing physician . At end study protocol ( 12 month ) patient 's HAART therapy manage primary physician .</brief_summary>
	<brief_title>A Study Neurological Effects Adding Maraviroc HAART Regimen Patients With HIV ( HANDmac )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Neurocognitive Disorders</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV Positive On HAART , plasma viral load &lt; 50 copies/ml previous 12 month Able provide inform consent HAND diagnosis , symptom progression within previous 6 month NonHIV relate neurological disorder active central nervous system ( CNS ) opportunistic infection ( assess full blood count , electrolytes , creatinine , glucose , liver funciton test , cryptococcal antigen , venereal disease research laboratory ( VDRL ) , MRI brain scan CSF analysis cell count , protein , glucose , culture , VDRL cryptococcal antigen ) Psychiatric disorder psychiatric axis Current major depression Current substance use disorder , severe substance use disorder within 12 month study entry Active Hepatitis C Virus ( HCV ) ( detectable HCV RNA ) History loss consciousness &gt; 1 hour Nonproficient English Medications know pharmacologically interact antiretrovirals ( ARVs ) Currently take entry inhibitor Pregnancy ( assessed urine pregnancy test )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HAND</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Neurocognitive</keyword>
	<keyword>Neurology</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>HIV Associated Neurocognitive Disorders</keyword>
</DOC>